MARK2 and neoplasm: miR-511-3p is upregulated in MRC1+ TAMs and suppresses tumor-promoting genes, including proteolytic enzymes and other extracellular matrix-remodeling molecules, thereby inhibiting tumor growth by targeting Rho-dependent kinase-2 (Rock2), a serine/threonine kinase that regulates cell cytoskeleton contractility [138,139].